Here is one that was approved a while back ago, but uptake has been slow. Eucrisa, otherwise known as crisaborole, is a phosphodiesterase-4 (PDE-4) inhibitor which is indicated for the treatment of mild to moderate atopic dermatitis in ages 2 years and up.
Mechanism of Action:
Crisaborole inhibits the enzyme PDE-4, which in turn, increases cAMP levels, thereby reducing cytokine signalling. This results in a decrease in inflammation present in atopic dermatitis.
Dosing: A thin layer of ointment to the area twice daily. Can be used anywhere (including on the face and thin areas).
-Application site pain (burning/stinging)
Eucrisa was well-tolerated by most patients.
Role in Therapy
The role of Eucrisa is quite limited because there are no trials in direct comparison to topical corticosteroids. There is also not much long-term safety evidence either since trials were 4 weeks in duration.
The only possible advantage would be as an alternative to topical steroids, which can cause skin atrophy and thinning. It could also be an alternative to topical calcineurin inhibitors since patients may have some concerns about links to skin cancer.
However, if patients have failed these two topical agents, most likely patients would consider oral agents rather than trying a third agent such as Eucrisa. In general, Eucrisa was well-tolerated with few side effects.